Matisse Pharmaceuticals B.V.

Matisse Pharmaceuticals B.V. is a biopharmaceutical clinical stage company dedicated to developing a product portfolio of safe and innovative therapies for disease indications characterized by elevated levels of freely circulating cytotoxic histones. These indications include severe and potentially life-threatening conditions, such as sepsis and septic shock. To obtain efficacy and safety data on its investigational medicines, Matisse conducts clinical trials that may be used to support marketing approval of the product by the European Medicines Agency (EMA), United States Food and Drug Administration (US FDA) and other regulatory authorities, with the aim of subsequent product accessibility to patients. 

Matisse is committed to provide access to its investigational medicines to patients as early and as widely as feasible, in careful consideration of the current progress of the applicable clinical and manufacturing development. Matisse seeks to retain the ability to manufacture and supply investigational medicines in a fair and equitable manner and in a volume that assures adequate supply for ongoing clinical trials and development programs. At this time, Matisse is therefore not in a position to provide its investigational medicines on an expanded access basis. For patients seeking access to our investigational medicines, participation in one of Matisse‘s clinical trials is the most appropriate way. To learn more about available clinical trials by Matisse, please visit https://www.matissepharmaceuticals.com/, or visit https://clinicaltrials.gov and search by sponsor “Matisse Pharmaceuticals“.

Matisse will revisit this policy at regular intervals and aims to update it once development proceeds. 

If you have additional questions, please speak with your physician or contact Matisse at clinical@matissepharmaceuticals.com.